Bayer Schering/Sonus’ Tocosol Paclitaxel Fails Phase III Pivotal Breast Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Tocosol paclitaxel Phase III trial fails to meet primary endpoint on noninferiority compared to Taxol control arm; trials discontinued, agreement with Bayer Schering could end, Sonus announces.